FMP

FMP

Enter

CDTX - Cidara Therapeutics, Inc.

Profile of Cidara Therapeutics, Inc.(CDTX), Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and comme

photo-url-https://financialmodelingprep.com/image-stock/CDTX.png

Cidara Therapeutics, Inc.

CDTX

NASDAQ

0.879 USD

0.0366 (4.17%)

About

ceo

Dr. Jeffrey L. Stein Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.cidara.com

exchange

NASDAQ

Description

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

CIK

0001610618

ISIN

US1717571079

CUSIP

171757107

Address

6310 Nancy Ridge Drive

Phone

858 752 6170

Country

US

Employee

73

IPO Date

Apr 15, 2015

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep